3D graphic showing blood cells passing CD34 beads for enrichment of CD34+ cells in graft engineering
3D graphic showing blood cells passing CD34 beads for enrichment of CD34+ cells in graft engineering
Logo

Efficient CD45RA+ cell depletion generates memory T cells to fight infection

Allogeneic hematopoietic stem cell transplantation (HSCT) has demonstrated experimentally that donor-derived memory T cells provide immunologic memory against numerous invaders but are less alloreactive than naive T cells.1–3 This feature has been used in the clinic with HSCT and other settings to prevent or treat opportunistic infections.4–6 Memory T cell products for clinical research use can be manufactured within 4–7 hours in a closed and sterile system using CliniMACS® CD45RA Reagents on the CliniMACS Prodigy® or CliniMACS Plus Instrument.

Research studies show memory T cell activity against infections

Opportunistic infections are a significant problem for patients with an immune system compromised by an underlying disease, intervention like HSCT, or medication like immunosuppressants for solid organ transplantation. Reports dating back to 2013 describe the experimental use of donor-derived CD45RA-depleted products in allogeneic HSCT to protect recipients against certain infections that the donor has experienced during a lifetime.

CliniMACS CD45RA-depleted products have been used experimentally in allogeneic HSCT to enhance immune reconstitution and as a treatment or prophylaxis against refractory opportunistic infections.7–9 In HSCT, CD45RA-depleted cells have been combined with CD34+ enriched or TCRα/β-depleted4,5 grafts and have been added to post-transplantation cyclophosphamide-based haploidentical transplantations, either directly as part of the graft10 or after administration to treat infections7. Other immunocompromised subjects, such as solid organ transplantation patients, have also received donor-derived memory T cells to overcome drug-resistant opportunistic infections, such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), BK virus (BKV), Aspergillus, and in the context of EBV-related lymphoma.6 A recently published case demonstrated the resolution of a parvovirus infection using CD45RA-depleted memory T cells.11 Additionally, memory T cells from familial donors have been administered to non-HSCT immunosuppressed patients as prophylaxis against refractory viral infections.6,12

Get an overview of all our solutions for graft engineering.

What is CD45RA?

Prior to clinical applications, studies in mouse models showed that the potential for alloreactivity is high in the naive T cell compartment and significantly reduced in the memory T cell compartment.13 In contrast, memory T cells have a markedly reduced alloreactive potential in HSCT settings.1–3 The CD45RA marker is an isoform of the CD45 family that is present on naive T cells but not on CD45RO+ central and effector memory T cells.14,15 Thus, depleting CD45RA+ cells in a cellular product passively enriches memory T cells that can fight infection and removes naive T cells that can potentially induce graft-versus-host disease (GVHD).1,2* The depletion also removes approximately 100% of B cells, most NK cells, and other white blood cell types, such as CD34+ stem cells, from mobilized leukapheresis products.16

CD45RA is not a typical T cell marker but is suited to deplete alloreactivity from a product in one step, leaving very specific, potentially beneficial memory T cells. Thus, CD45RA depletion is a key production option for clinical applications.

* In exceptional cases, donors may have CD45+ memory T cells. This should be tested prior to any clinical research application.1

Two complete workflows for CD45RA depletion

Miltenyi Biotec offers two technical options for the depletion of CD45RA+ cells from leukapheresis products. The CliniMACS Plus System automates clinical-scale depletion of unwanted CD45RA+ cells from blood products in a closed and sterile system. The CliniMACS Prodigy Platform allows expanding the automated magnetic depletion of CD45RA+ cells with all prior washing and labeling steps.

The generation of memory T cells with the CliniMACS Plus or CliniMACS Prodigy Platform.

Automating the manufacturing of your memory T cell products

The depletion of CD45RA+ cells from a leukapheresis product is automated on the CliniMACS Prodigy or the CliniMACS Plus. The process is highly reproducible and standardized. The starting fraction is labeled with antibodies against the surface marker CD45RA. Subsequent magnetic separation generates a target cell fraction passively enriched for memory T cells.

Video

Automated magnetic depletion of CD45RA+ naive T cells with the CliniMACS CD45RA Reagents

The combination of CliniMACS CD45RA Reagents and the CliniMACS Prodigy or the CliniMACS Plus allows for the automated and GMP-compliant depletion of CD45RA+ naive T cells.

Scientific narratives: CD45RA+ cell depletion use cases

The following is a sample of scientific presentations by experts in stem cell transplantation who have examined the safety and benefit of enriching memory T cells in grafts. They show data on tolerability, GVHD assessment, infection rates, and immune reconstitution.

Recorded talk

Safety and efficacy of a memory (CD45RA-depleted) T cell donor lymphocyte infusion (DLI) in pediatric HSCT recipients

Antonio Perez, a guest speaker for the Miltenyi Biotec Corporate Symposium at EBMT 2023, discusses approaches to ameliorate transplantation-associated lymphopenia using the CliniMACS CD34 Enrichment System and CliniMACS CD45RA Depletion System to generate a highly pure CD34-enriched stem cell graft with additional memory T cells. He presents clinical outcome data, including assessment of GVHD and immune reconstitution.

Recorded talk

Feasibility and efficacy of CD45RA-depleted DLI after haploidentical transplantation with post-transplantation cyclophosphamide

Speaking at the Miltenyi Biotec Corporate Symposium of the 48th EBMT Annual Meeting in 2022, Luca Castagna presents data on the use of allogeneic CD45RA-depleted lymphocyte infusion to reduce viral infection after haploidentical transplantation. He demonstrates that a product generated with the CliniMACS CD45RA Depletion System was well tolerated and discusses the next steps of his research.

Recorded talk

CD45RA+ naive T cell depletion of PBSC grafts for prevention of chronic GVHD

Marie Bleakley spoke at the Miltenyi Biotec Corporate Symposium of EBMT 2022 about her research on strategies to prevent chronic GVHD in allogeneic HSCT. Combining the CliniMACS CD34 Enrichment System and the CliniMACS CD45RA Depletion System, she generated stem cell grafts from peripheral blood that lacked naive T cells and showed encouraging patient outcomes.

Selected references: Learn how CliniMACS Instruments support graft engineering in HSCT

Icon selected references in turquoise

Stay up to date with influential publications across major graft engineering topics, from haploidentical and matched HSCT to stem cell boost, infections, and separation process performance.

Get personalized support on enrichment of memory T cells for graft engineering

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. For complete regulatory notes, please click here.